Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial.

MLA

Verhoef, Viola M. J., et al. “Triage by Methylation-Marker Testing versus Cytology in Women Who Test HPV-Positive on Self-Collected Cervicovaginal Specimens (PROHTECT-3): A Randomised Controlled Non-Inferiority Trial.” The Lancet. Oncology, vol. 15, no. 3, Mar. 2014, pp. 315–22. EBSCOhost, https://doi.org/10.1016/S1470-2045(14)70019-1.

APA

Verhoef, V. M. J., Bosgraaf, R. P., van Kemenade, F. J., Rozendaal, L., Heideman, D. A. M., Hesselink, A. T., Bekkers, R. L. M., Steenbergen, R. D. M., Massuger, L. F. A. G., Melchers, W. J. G., Bulten, J., Overbeek, L. I. H., Berkhof, J., Snijders, P. J. F., & Meijer, C. J. L. M. (2014). Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. The Lancet. Oncology, 15(3), 315–322. https://doi.org/10.1016/S1470-2045(14)70019-1

Chicago

Verhoef, Viola M J, Remko P Bosgraaf, Folkert J van Kemenade, Lawrence Rozendaal, Daniëlle A M Heideman, Albertus T Hesselink, Ruud L M Bekkers, et al. 2014. “Triage by Methylation-Marker Testing versus Cytology in Women Who Test HPV-Positive on Self-Collected Cervicovaginal Specimens (PROHTECT-3): A Randomised Controlled Non-Inferiority Trial.” The Lancet. Oncology 15 (3): 315–22. doi:10.1016/S1470-2045(14)70019-1.